Nathaniel Keller, MD
Psychiatry · Orlando, FLNPI 1144411844
Payments from drug & device makers
Across 64 payments — averaging $187.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$11K
- AbbVie$238
- Bausch Health US, LLC$158
- Lundbeck LLC$132
- Sunovion Pharmaceuticals Inc.$89
- Teva Pharmaceuticals USA, Inc.$81
- plus $195 from 8 others
What the payments were for
- Speaking & faculty fees$10,96891%
- Travel & lodging$50%
- Food & beverage$1,0359%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $11,115 |
| AbbVie | 16 | $238 |
| Bausch Health US, LLC | 9 | $158 |
| Lundbeck LLC | 7 | $132 |
| Sunovion Pharmaceuticals Inc. | 5 | $89 |
| Teva Pharmaceuticals USA, Inc. | 4 | $81 |
| Ironshore Pharmaceuticals Inc. | 3 | $48 |
| Johnson & Johnson | 2 | $33 |
| Brainsway USA Inc | 1 | $24 |
| Shire North American Group Inc | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Rhodes Pharmaceuticals L.p. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Neuronetics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRINTELLIX$11,076
How this compares
$12,008 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 33 | $4,956 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 26 | $2,450 |
| Bupropion XlBupropion Hcl | 114 | $2,409 |
| Sertraline Hcl | 188 | $1,712 |
| Clonazepam | 172 | $1,437 |
| Alprazolam | 237 | $1,182 |
| Duloxetine Hcl | 74 | $1,016 |
| Lamotrigine | 44 | $898 |
| Quetiapine Fumarate | 47 | $897 |
| Fluoxetine Hcl | 88 | $830 |
| Paroxetine Hcl | 47 | $805 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 16 | $668 |
| Trazodone Hcl | 61 | $564 |
| Escitalopram Oxalate | 41 | $515 |
| Mirtazapine | 31 | $503 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Orlando
- Linda HarperOrlando$8.5M
- Morteza NadjafiOrlando$5.3M
- David MedinaOrlando$1.1M
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.